Familial hypercholesterolemia (FH) is a genetic and hereditary disorder, which leads to a high level of LDL (bad) cholesterol. The condition begins at birth and can cause heart attacks at an early age.
FH is generally a silent disease, except for HoFH. HoFH typically presents with pathognomonic physical findings in childhood, including xanthelasmas, tendon xanthomas, and corneal arcus. By contrast, in the Spanish Familial Hypercholesterolemia Cohort study, xanthomas and corneal arcus were present in less than 15% and 30% of patients with heterozygous FH (HeFH), respectively. However, the prevalence of these findings increases with age in untreated individuals.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-market-report
The Familial Hypercholesterolemia market report also covers emerging drugs, current treatment practices, Familial Hypercholesterolemia market share of the individual therapies, current and forecasted Familial Hypercholesterolemia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Familial Hypercholesterolemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Familial Hypercholesterolemia Market Key Facts
-
The total prevalent population of Familial Hypercholesterolemia in the seven major markets was found to be 2,367,466 in 2017. However, the total diagnosed prevalent patient population of FH was 965,405 in 2017.
-
The diagnosed prevalence of Familial Hypercholesterolemia was found to be 244,214 in the United States in 2017.
-
In 2017, Japan accounted for 221,519 cases of the diagnosed prevalent population of Familial Hypercholesterolemia.
-
Among the FH patients, the diagnosed prevalence was found to be highest in the United States among the seven major markets.
Key Benefits of Familial Hypercholesterolemia Market Report
-
Familial Hypercholesterolemia market report provides an in-depth analysis of Familial Hypercholesterolemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Familial Hypercholesterolemia market report will help in developing business strategies by understanding the Familial Hypercholesterolemia Market trends & developments, key players, and future market competition that will shape and drive the Familial Hypercholesterolemia market in the upcoming years.
-
The Familial Hypercholesterolemia market report covers Familial Hypercholesterolemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Familial Hypercholesterolemia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Familial Hypercholesterolemia Market
The Familial Hypercholesterolemia market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Familial Hypercholesterolemia market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Familial Hypercholesterolemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Familial Hypercholesterolemia Treatment Market
Early diagnosis and treatment of Familial Hypercholesterolemia are vital to reduce the risk of premature atherosclerotic cardiovascular disease and death. The goal of treatment is to reduce LDL-C by 50% from baseline levels with lifestyle modification, pharmacologic lipid-lowering therapy, and LDL apheresis and in rare cases, liver transplantation.
The expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of FH. Owing to the positive outcomes of the several products during the developmental stage by key players such as the market is expected to witness a significant positive shift in the FH Market Size.
Familial Hypercholesterolemia Epidemiology
In general, an estimated 20 million people worldwide have FH. Despite the high prevalence and increased risk of premature ASCVD in untreated patients, less than 1% are diagnosed with FH worldwide. However, according to the Centers for Disease Control and Prevention, the US prevalence of definite/probable FH is 0.5%.
The Familial Hypercholesterolemia epidemiology section covers insights about the historical and current Familial Hypercholesterolemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Familial Hypercholesterolemia Drugs Uptake and Key Market Players
The Familial Hypercholesterolemia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Hypercholesterolemia market or expected to get launched in the market during the study period. The analysis covers Familial Hypercholesterolemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Familial Hypercholesterolemia market size is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise efficient treatment options. The familial Hypercholesterolemia pipeline is robust and possesses multiple potential drugs in late and mid-stage developments to be launched in the near future.
Familial Hypercholesterolemia Companies:
Regeneron Pharmaceuticals
Novartis
LIB Therapeutics
NeuroBo Pharmaceuticals
Madrigal Pharmaceuticals
Jiangsu HengRui Medicine
And many others.
Familial Hypercholesterolemia Therapies covered in the report include:
Evinacumab (REGN1500)
Inclisiran
LIB003
Gemcabene
SHR-1209
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Familial Hypercholesterolemia Competitive Intelligence Analysis
4. Familial Hypercholesterolemia Market Overview at a Glance
5. Familial Hypercholesterolemia Disease Background and Overview
6. Familial Hypercholesterolemia Patient Journey
7. Familial Hypercholesterolemia Epidemiology and Patient Population
8. Familial Hypercholesterolemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Familial Hypercholesterolemia Unmet Needs
10. Key Endpoints of Familial Hypercholesterolemia Treatment
11. Familial Hypercholesterolemia Marketed Products
12. Familial Hypercholesterolemia Emerging Therapies
13. Familial Hypercholesterolemia Seven Major Market Analysis
14. Attribute Analysis
15. Familial Hypercholesterolemia Market Outlook (7 major markets)
16. Familial Hypercholesterolemia Access and Reimbursement Overview
17. KOL Views on the Familial Hypercholesterolemia Market.
18. Familial Hypercholesterolemia Market Drivers
19. Familial Hypercholesterolemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports By DelveInsight
Familial Hypercholesterolemia Epidemiology Forecast
DelveInsight’s ‘Familial Hypercholesterolemia (FH) – Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted analysis of Familial Hypercholesterolemia for the 7MM.
Familial Hypercholesterolemia Pipeline Insights
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/